FAQ

Dr. Noon Fundus is an assistive software designed to detect and aid in the diagnosis of retinal diseases (such as diabetic retinopathy, macular degeneration, epiretinal membrane, retinal hemorrhage/occlusion, and other retinal disorders), glaucoma suspects, and cataract suspects.

In a clinical trial conducted at Seoul Asan Medical Center and Gangnam Severance Hospital, involving 182 patients with retinal conditions and 183 normal controls, the test demonstrated excellent diagnostic accuracy with the following AUC scores* for each condition:
● Retinal diseases: 0.93
● Glaucoma suspect: 0.95
● Cataract suspect: 0.96
In addition, agreement rates with ophthalmologists regarding the presence or absence of disease were as follows:
● Positive agreement: 92.39%
● Negative agreement: 95.48%
● Overall agreement: 93.91%

These results validate Dr. Noon Fundus as a high-performing diagnostic support software for ophthalmic conditions.
*AUC (Area Under the Curve): A performance metric for classification models, representing the area under the ROC curve. AUC values close to 1 indicate excellent classification performance. Generally, a value above 0.7 is considered good.
* Clinical Trial Reference: Multicenter, randomized, evaluator-blinded, retrospective, agreement validation confirmatory trial evaluating the efficacy of Dr. Noon for Fundus Screening (current product name - Dr. Noon Fundus) in detecting ocular abnormalities using retinal fundus images.

Unlike Heart CT or ultrasound assessments, Dr. Noon CVD poses no radiation risk and allows frequent imaging for monitoring. It also delivers accuracy that surpasses ultrasound-based methods.

It is validated for individuals aged 20–80, with no prior cardiovascular history, no heart surgery or intervention, and no eye surgery within the past 6 months. This test is predictive, not diagnostic, so it is not suited for acute cardiac symptoms (e.g., chest pain, shortness of breath), where emergency tests like ECG or echocardiogram are necessary.
* Evidence: https://doi.org/10.1093/jamia/ocad199

Yes. Even within the high-risk group (score 41+), a higher score indicates greater risk. Age distribution also matters—for example, a high-risk result in your 30s (seen in <5% of this group) signals a need for intensive management, while in the 70s age group, risk should be

A dark cloth to simulate a dim room is recommended. Artificial tears can also help obtain clearer images, especially for elderly patients who may have dry eye.
* Evidence: https://doi.org/10.1364/OL.41.001981: Dry eye reduces OCT image quality.

Even if not visible to the naked eye, AI can detect subtle details. Key areas like the optic disc and vascular arcades should be visible in the image to ensure reliable analysis.

Yes. The AI was trained on data including patients with eye conditions. Bilateral imaging is generally recommended. For unilateral diseases like cataract, Age-related Macular Degeneartion, or glaucoma, it is best to take two images of the healthy eye.

If more than 6 months have passed since the surgery, retinal imaging is possible.

If a fundus photo has already been taken using the standard method, you only need to upload the image file along with the patient’s age and gender for analysis. Since only the image file is needed, you can also upload all the fundus photos taken throughout the day in a batch for processing.